ADAP Adaptimmune Therapeutics plc gains 33% Sep 19, 2017

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead program includes NY-ESO cancer antigen, which is in Phase 1/2 clinical trials for the treatment of patients with solid tumors, as well as hematological cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune Therapeutics plc is also developing MAGE A-10 TCR that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and other solid tumors; and Alpha Fetoprotein TCR therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom. http://www.priceseries.com/trade/ADAP-Adaptimmune-Therapeutics-plc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2017082820170919.html